FDAnews Announces -- FDA 483s, Warning Letters & Enforcement Trends Webinar, Nov. 25, 2019
Ever receive a 483 or warning letter? Want to make sure it doesn't happen again?
FALLS CHURCH, Va., Nov. 13, 2019 /PRNewswire-PRWeb/ -- FDA 483s, Warning Letters & Enforcement Trends
An FDAnews Webinar
Monday, Nov. 25, 2019, 1:30 p.m. – 3:00 p.m. EST
https://www.fdanews.com/483swarningletters
What's the chance of getting hit with a 483 or warning letter in 2020? And what can one do to avoid it?
Get an early warning on problem areas to focus on. Mark the calendar for Monday, Nov. 25.
Former FDA assistant counsel John Fuson Esq. of Crowell & Moring LLP and his colleague Chalana Damron Esq. take attendees on a deep dive inside FDA enforcement thinking. Attendees will discover what the agency is pinpointing and what it's soft-pedaling:
- Enforcement trends: 2019 FDA enforcement activity — 483s and warning letters — vs. prior years
- Most prevalent targets of FDA inspections
- GMP violations most often cited in 483s and in warning letters
- Managing inspections to minimize risk of escalation
- How lawsuits are born: The role that FDA enforcement actions play
Strengthen quality and compliance systems!
Interested in registering multiple sites?
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
to learn about our special multisite discount.
Webinar Details:
FDA 483s, Warning Letters & Enforcement Trends
An FDAnews Webinar
Monday, Nov. 25, 2019, 1:30 p.m. – 3:00 p.m. EST
https://www.fdanews.com/483swarningletters
Tuition:
$287 per site
Easy Ways to Register:
Online: https://www.fdanews.com/483swarningletters
By phone: 888-838-5578 or 703-538-7600
About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations
SOURCE FDAnews

Share this article